JP2023545508A5 - - Google Patents
Info
- Publication number
- JP2023545508A5 JP2023545508A5 JP2023523007A JP2023523007A JP2023545508A5 JP 2023545508 A5 JP2023545508 A5 JP 2023545508A5 JP 2023523007 A JP2023523007 A JP 2023523007A JP 2023523007 A JP2023523007 A JP 2023523007A JP 2023545508 A5 JP2023545508 A5 JP 2023545508A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091875P | 2020-10-14 | 2020-10-14 | |
| US63/091,875 | 2020-10-14 | ||
| PCT/US2021/055102 WO2022081925A1 (en) | 2020-10-14 | 2021-10-14 | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545508A JP2023545508A (ja) | 2023-10-30 |
| JPWO2022081925A5 JPWO2022081925A5 (https=) | 2024-10-22 |
| JP2023545508A5 true JP2023545508A5 (https=) | 2024-10-22 |
Family
ID=81208646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523007A Pending JP2023545508A (ja) | 2020-10-14 | 2021-10-14 | Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230339902A1 (https=) |
| EP (1) | EP4228639A4 (https=) |
| JP (1) | JP2023545508A (https=) |
| KR (1) | KR20230107569A (https=) |
| CN (1) | CN116783180A (https=) |
| AU (1) | AU2021361043A1 (https=) |
| CA (1) | CA3194169A1 (https=) |
| IL (1) | IL302038A (https=) |
| MX (1) | MX2023004374A (https=) |
| WO (1) | WO2022081925A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN118201923A (zh) * | 2021-10-15 | 2024-06-14 | 海南先声再明医药股份有限公司 | 三环类化合物 |
| EP4540241A1 (en) * | 2022-06-16 | 2025-04-23 | Monte Rosa Therapeutics AG | Substituted piperidines as ck1a degraders |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN116655595A (zh) * | 2023-06-05 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 2,6-哌啶二酮衍生物及其制备和用途 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| WO2025006783A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras |
| WO2025097092A1 (en) * | 2023-11-02 | 2025-05-08 | Neomorph, Inc. | Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6h-pyrrolo[3,4-b]pyridin-6-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025162410A1 (zh) * | 2024-01-31 | 2025-08-07 | 微境生物医药科技(上海)有限公司 | 新型蛋白降解剂及抗体-蛋白降解剂偶联物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| CN105985282B (zh) * | 2015-01-28 | 2020-12-08 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用 |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11220515B2 (en) * | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| EP3813834B1 (en) * | 2018-06-29 | 2025-03-26 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) * | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| KR20210106437A (ko) * | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| EP3924055B1 (en) * | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) * | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CN120172958A (zh) * | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| WO2020243379A1 (en) * | 2019-05-31 | 2020-12-03 | Celgene Corporation | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
| US20240383886A1 (en) * | 2019-12-20 | 2024-11-21 | Calico Life Sciences Llc | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| MX2023001545A (es) * | 2020-08-07 | 2023-05-03 | C4 Therapeutics Inc | Terapias ventajosas para trastornos mediados por ikaros o aiolos. |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| EP4228625A4 (en) * | 2020-10-14 | 2026-01-14 | C4 Therapeutics Inc | TRICYCLIC HETEROBFUNCTIONAL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION |
-
2021
- 2021-10-14 IL IL302038A patent/IL302038A/en unknown
- 2021-10-14 CN CN202180083722.6A patent/CN116783180A/zh active Pending
- 2021-10-14 WO PCT/US2021/055102 patent/WO2022081925A1/en not_active Ceased
- 2021-10-14 KR KR1020237015798A patent/KR20230107569A/ko active Pending
- 2021-10-14 EP EP21881142.0A patent/EP4228639A4/en active Pending
- 2021-10-14 MX MX2023004374A patent/MX2023004374A/es unknown
- 2021-10-14 CA CA3194169A patent/CA3194169A1/en active Pending
- 2021-10-14 AU AU2021361043A patent/AU2021361043A1/en active Pending
- 2021-10-14 JP JP2023523007A patent/JP2023545508A/ja active Pending
-
2023
- 2023-04-14 US US18/134,985 patent/US20230339902A1/en active Pending